GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
Rutherford, NJ & Cambridge, UK, April 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, and The Technology Partnership (“TTP”), today announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor (“CBGM”), suggesting sensor longevity beyond three years, a year longer than the Company previously announced.
- Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors.
- This in silico modeling specifically evaluated the expected longevity of the Glucotrack CBGM sensor implementation.
- The CBGM sensor leverages well-established cardiovascular technology to directly measure blood glucose intravenously, providing more rapid glucose monitoring results without the 15-20-minute lag seen with interstitial glucose sensors.
- TTP’s knowledge and skills have been instrumental in evaluating and extending the projected longevity of the Glucotrack CBGM sensor.